In vitro and in vivo models for analysis of resistance to anticancer molecular therapies

Current Medicinal Chemistry

Volumn 21, Issue 14, 2014, Pages 1595-1606

  Rosa, Roberta ^a   Monteleone, Francesca ^b,c   Zambrano, Nicola ^a,b,c   Bianco, Roberto ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c Associazione Culturale DiSciMuS   (Italy)

Author keywords

Anticancer molecular therapies; Molecular modelling; Tumour

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER GENETICS; CANCER RESEARCH; DRUG RESEARCH; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDICINAL CHEMISTRY; MOLECULAR THERAPY; NONHUMAN; ONCOLOGY; REVIEW; ANIMAL; BIOLOGICAL MODEL; DRUG RESISTANCE; GENOTYPE; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENOTYPE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84899819988     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990226     Document Type: Review

References (72)

1. Gerber, D. E. Targeted therapies: a new generation of cancer treatments. Am. Fam. Physician, 2008, 77(3), 311-319.
2. Nardella, C.; Lunardi, A.; Patnaik, A.; Cantley, L. C.; Pandolfi, P. P. The APL paradigm and the co-clinical trial project. Cancer Discov., 2011, 1(2), 108-116.
3. Nasr, R.; de The, H. Eradication of acute promyelocytic leukemiainitiating cells by PML/RARA-targeting. Int. J. Hematol., 2010, 91(5), 742-747.
4. Fojo, T.; Parkinson, D. R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res., 2010, 16(24), 5972-5980.
5. Learn, C. A.; Hartzell, T. L.; Wikstrand, C. J.; Archer, G. E.; Rich, J. N.; Friedman, A. H.; Friedman, H. S.; Bigner, D. D.; Sampson, J. H. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin. Cancer Res., 2004, 10(9), 3216-3224.
6. Bianco, R.; Shin, I.; Ritter, C. A.; Yakes, F. M.; Basso, A.; Rosen, N.; Tsurutani, J.; Dennis, P. A.; Mills, G. B.; Arteaga, C. L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene, 2003, 22(18), 2812-2822.
7. Nagata, Y.; Lan, K. H.; Zhou, X.; Tan, M.; Esteva, F. J.; Sahin, A. A.; Klos, K. S.; Li, P.; Monia, B. P.; Nguyen, N. T.; Hortobagyi, G. N.; Hung, M. C.; Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6(2), 117-127.
8. Bianco, R.; Troiani, T.; Tortora, G.; Ciardiello, F. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr. Relat. Cancer, 2005, 12 Suppl 1, S159-S171.
9. Efferth, T. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr. Med. Chem., 2012, 19(33), 5735-5744.
10. Morgillo, F.; Bareschino, M. A.; Bianco, R.; Tortora, G.; Ciardiello, F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation, 2007, 75(9), 788-799.
11. Ellis, L. M.; Hicklin, D. J. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin. Cancer Res., 2009, 15(24), 7471-7478.
12. Michalczyk, A.; Kluter, S.; Rode, H. B.; Simard, J. R.; Grutter, C.; Rabiller, M.; Rauh, D. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg. Med. Chem., 2008, 16(7), 3482-3488.
13. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J. L.; Van Laethem, J. L.; Maurel, J.M; Richardson, G.; Wolf, M.; Amado, R. G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J. Clin. Oncol., 2007, 25(13), 1658-1664.
14. Engelman, J. A.; Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin. Cancer Res., 2008, 14(10), 2895-2899.
15. Crespan, E.; Zucca, E.; Maga, G. Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models. Curr. Med. Chem., 2011, 18(19), 2836-2847.
16. Bareschino, M. A.; Schettino, C.; Colantuoni, G.; Rossi, E.; Rossi, A.; Maione, P.; Ciardiello, F.; Gridelli, C. The role of antiangiogenetic agents in the treatment of breast cancer. Curr. Med. Chem., 2011, 18(33), 5022-5032.
17. Wahl, O.; Oswald, M.; Tretzel, L.; Herres, E.; Arend, J.; Efferth, T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr. Med. Chem., 2011, 18(21), 3136-3155.
18. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer, 2008, 8(8), 592-603.
19. Yang, W.; Soares, J.; Greninger, P.; Edelman, E. J.; Lightfoot, H.: Forbes, S.: Bindal, N.; Beare, D.; Smith, J. A.; Thompson, I. R.; Ramaswamy, S.; Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Benes, C.; McDermott, U.; Garnett, M. J. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res., 2012, 41(D1), D955-961.
20. Forbes, S. A.; Bindal, N.; Bamford, S.; Cole, C.; Kok, C. Y.; Beare, D.; Jia, M.; Shepherd, R.; Leung, K.; Menzies, A.; Teague, J. W.; Campbell, P. J.; Stratton, M. R.; Futreal, P. A. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res., 2010, 39(Database issue), D945-950.
21. Garnett, M. J.; Edelman, E. J.; Heidorn, S. J.; Greenman, C. D.; Dastur, A.; Lau, K. W.; Greninger, P.; Thompson, I. R.; Luo, X.; Soares, J.; Liu, Q.; Iorio, F.; Surdez, D.; Chen, L.; Milano, R. J.; Bignell, G. R.; Tam, A. T.; Davies, H.; Stevenson, J. A.; Barthorpe, S.; Lutz, S. R.; Kogera, F.; Lawrence, K.; McLaren-Douglas, A.; Mitropoulos, X.; Mironenko, T.; Thi, H.; Richardson, L.; Zhou, W.; Jewitt, F.; Zhang, T.; O'Brien, P.; Boisvert, J. L.; Price, S.; Hur, W.; Yang, W.; Deng, X.; Butler, A.; Choi, H. G.; Chang, J. W.; Baselga, J.; Stamenkovic, I.; Engelman, J. A.; Sharma, S. V.; Delattre, O.; Saez-Rodriguez, J.; Gray, N. S.; Settleman, J.; Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Ramaswamy, S.; McDermott, U.; Benes, C. H. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 2012, 483(7391), 570-575.
22. Barretina, J.; Caponigro, G.; Stransky, N.; Venkatesan, K.; Margolin, A. A.; Kim, S.; Wilson, C. J.; Lehar, J.; Kryukov, G. V.; Sonkin, D.; Reddy, A.; Liu, M.; Murray, L.; Berger, M. F.; Monahan, J. E.; Morais, P.; Meltzer, J.; Korejwa, A.; Jane-Valbuena, J.; Mapa, F. A.; Thibault, J.; Bric-Furlong, E.; Raman, P.; Shipway, A.; Engels, I. H.; Cheng, J.; Yu, G. K.; Yu, J.; Aspesi, P., Jr.; de Silva, M.; Jagtap, K.; Jones, M. D.; Wang, L.; Hatton, C.; Palescandolo, E.; Gupta, S.; Mahan, S.; Sougnez, C.; Onofrio, R. C.; Liefeld, T.; MacConaill, L.; Winckler, W.; Reich, M.; Li, N.; Mesirov, J. P.;Gabriel, S. B.; Getz, G.; Ardlie, K.; Chan, V.; Myer, V. E.; Weber, B. L.; Porter, J.; Warmuth, M.; Finan, P.; Harris, J. L.; Meyerson, M.; Golub, T. R.; Morrissey, M. P.; Sellers, W. R.; Schlegel, R.; Garraway, L. A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature, 2012, 483(7391), 603-607.
23. Tanner, M.; Kapanen, A. I.; Junttila, T.; Raheem, O.; Grenman, S.; Elo, J.; Elenius, K.; Isola, J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol. Cancer Ther., 2004, 3(12), 1585-1592.
24. Nagy, P.; Friedlander, E.; Tanner, M.; Kapanen, A. I.; Carraway, K. L.; Isola, J.; Jovin, T. M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res., 2005, 65(2), 473-482.
25. Christianson, T. A.; Doherty, J. K.; Lin, Y. J.; Ramsey, E. E.; Holmes, R.; Keenan, E. J.; Clinton, G. M. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res., 1998, 58(22), 5123-5129.
26. Kurebayashi, J.; Otsuki, T.; Tang, C. K.; Kurosumi, M.; Yamamoto, S.; Tanaka, K.; Mochizuki, M.; Nakamura, H.; Sonoo, H. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br. J. Cancer, 1999, 79(5-6), 707-717.
27. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350(21), 2129-2139.
28. Sgambato, A.; Casaluce, F.; Maione, P.; Rossi, A.; Rossi, E.; Napolitano, A.; Palazzolo, G.; Bareschino, M. A.; Schettino, C.; Sacco, P. C.; Ciadiello, F.; Gridelli, C. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. Curr. Med. Chem., 2012, 19(20), 3337-3352.
29. Shigematsu, H.; Lin, L.; Takahashi, T.; Nomura, M.; Suzuki, M.; Wistuba,, II; Fong, K. M.; Lee, H.; Toyooka, S.; Shimizu, N.; Fujisawa, T.; Feng, Z.; Roth, J. A.; Herz, J.; Minna, J. D.; Gazdar, A. F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst., 2005, 97(5), 339-346.
30. Orzaez, M.; Guevara, T.; Sancho, M.; Perez-Paya, E. Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment. Cell Death Dis., 2012, 3, e415.
31. Milligan, S. A.; Burke, P.; Coleman, D. T.; Bigelow, R. L.; Steffan, J. J.; Carroll, J. L.; Williams, B. J.; Cardelli, J. A. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin. Cancer Res., 2009, 15(15), 4885-4894.
32. Gorzalczany, Y.; Gilad, Y.; Amihai, D.; Hammel, I.; Sagi-Eisenberg, R.; Merimsky, O. Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. Cancer Lett., 2012, 310(2), 207-215.
33. Rosa, R.; Melisi, D.; Damiano, V.; Bianco, R.; Garofalo, S.; Gelardi, T.; Agrawal, S.; Di Nicolantonio, F.; Scarpa, A.; Bardelli, A.; Tortora, G. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin. Cancer Res., 2011, 17(20), 6531-6541.
34. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J. ; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467(7315), 596-599.
35. Prahallad, A.; Sun, C.; Huang, S.; Di Nicolantonio, F.; Salazar, R.; Zecchin, D.; Beijersbergen, R. L.; Bardelli, A.; Bernards, R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483(7387), 100-103.
36. Yeh, T. C.; Marsh, V.; Bernat, B. A.; Ballard, J.; Colwell, H.; Evans, R. J.; Parry, J.; Smith, D.; Brandhuber, B. J.; Gross, S.; Marlow, A.; Hurley, B.; Lyssikatos, J.; Lee, P. A.; Winkler, J. D.; Koch, K.; Wallace, E. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res., 2007, 13(5), 1576-1583.
37. Balmanno, K.; Chell, S. D.; Gillings, A. S.; Hayat, S.; Cook, S. J. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int. J. Cancer, 2009, 125(10), 2332-2341.
38. Richmond, A.; Su, Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis. Model Mech., 2008, 1(2-3), 78-82.
39. Politi, K.; Pao, W. How genetically engineered mouse tumor models provide insights into human cancers. J. Clin. Oncol., 2011, 29(16), 2273-2281.
40. Cheon, D. J.; Orsulic, S. Mouse models of cancer. Annu. Rev. Pathol., 2010, 6, 95-119.
41. Shojaei, F.; Wu, X.; Malik, A. K.; Zhong, C.; Baldwin, M. E.; Schanz, S.; Fuh, G.; Gerber, H. P.; Ferrara, N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol., 2007, 25(8), 911-920.
42. Shojaei, F.; Ferrara, N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res., 2008, 68(14), 5501-5504.
43. Ulanet, D. B.; Ludwig, D. L.; Kahn, C. R.; Hanahan, D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc. Natl. Acad. Sci. U S A, 2010, 107(24), 10791-10798.
44. Clynes, R. A.; Towers, T. L.; Presta, L. G.; Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med., 2000, 6(4), 443-446.
45. Chen, Z.; Cheng, K.; Walton, Z.; Wang, Y.; Ebi, H.; Shimamura, T.; Liu, Y.; Tupper, T.; Ouyang, J.; Li, J.; Gao, P.; Woo, M. S.; Xu, C.; Yanagita, M.; Altabef, A.; Wang, S.; Lee, C.; Nakada, Y.; Pena, C. G.; Sun, Y.; Franchetti, Y.; Yao, C.; Saur, A.; Cameron, M. D.; Nishino, M.; Hayes, D. N.; Wilkerson, M. D.; Roberts, P. J.; Lee, C. B.; Bardeesy, N.; Butaney, M.; Chirieac, L. R.; Costa, D. B.; Jackman, D.; Sharpless, N. E.; Castrillon, D. H.; Demetri, G. D.; Janne, P. A.; Pandolfi, P. P.; Cantley, L. C.; Kung, A. L.; Engelman, J. A.; Wong, K. K. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature, 2012, 483(7391), 613-617.
46. Schenborn, E. T.; Goiffon, V. DEAE-dextran transfection of mammalian cultured cells. Methods Mol. Biol., 2000, 130, 147-153.
47. Kim, T. K.; Eberwine, J. H. Mammalian cell transfection: the present and the future. Anal. Bioanal. Chem., 2010, 397(8), 3173-3178.
48. Eichhorn, P. J.; Gili, M.; Scaltriti, M.; Serra, V.; Guzman, M.; Nijkamp, W.; Beijersbergen, R. L.; Valero, V.; Seoane, J.; Bernards, R.; Baselga, J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res., 2008, 68(22), 9221-9230.
49. Li, J.; Rix, U.; Fang, B.; Bai, Y.; Edwards, A.; Colinge, J.; Bennett, K. L.; Gao, J.; Song, L.; Eschrich, S.; Superti-Furga, G.; Koomen, J.; Haura, E. B. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol., 2010, 6(4), 291-299.
50. Li, J. L.; Sainson, R. C.; Oon, C. E.; Turley, H.; Leek, R.; Sheldon, H.; Bridges, E.; Shi, W.; Snell, C.; Bowden, E. T.; Wu, H.; Chowdhury, P. S.; Russell, A. J.; Montgomery, C. P.; Poulsom, R.; Harris, A. L. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo . Cancer Res., 2011, 71(18), 6073-6083.
51. Iorio, M. V.; Croce, C. M. microRNA involvement in human cancer. Carcinogenesis, 2012, 33(6), 1126-1133.
52. Garofalo, M.; Romano, G.; Di Leva, G.; Nuovo, G.; Jeon, Y. J.; Ngankeu, A.; Sun, J.; Lovat, F.; Alder, H.; Condorelli, G.; Engelman, J. A.; Ono, M.; Rho, J. K.; Cascione, L.; Volinia, S.; Nephew, K. P.; Croce, C. M. EGFR and MET receptor tyrosine kinasealtered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med., 2011, 18(1), 74-82.
53. Misale, S.; Yaeger, R.; Hobor, S.; Scala, E.; Janakiraman, M.; Liska, D.; Valtorta, E.; Schiavo, R.; Buscarino, M.; Siravegna, G.; Bencardino, K.; Cercek, A.; Chen, C. T.; Veronese, S.; Zanon, C.; Sartore-Bianchi, A.; Gambacorta, M.; Gallicchio, M.; Vakiani, E.; Boscaro, V.; Medico, E.; Weiser, M.; Siena, S.; Di Nicolantonio, F.; Solit, D.; Bardelli, A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486(7404), 532-536.
54. Di Nicolantonio, F.; Arena, S.; Gallicchio, M.; Bardelli, A. Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell Cycle, 2009, 9(1), 20-21.
55. Di Nicolantonio, F.; Arena, S.; Gallicchio, M.; Zecchin, D.; Martini, M.; Flonta, S. E.; Stella, G. M.; Lamba, S.; Cancelliere, C.; Russo, M.; Geuna, M.; Appendino, G.; Fantozzi, R.; Medico, E.; Bardelli, A. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc. Natl. Acad. Sci. U S A, 2008, 105(52), 20864-20869.
56. De Roock, W.; Jonker, D. J.; Di Nicolantonio, F.; Sartore-Bianchi, A.; Tu, D.; Siena, S.; Lamba, S.; Arena, S.; Frattini, M.; Piessevaux, H.; Van Cutsem, E.; O'Callaghan, C. J.; Khambata-Ford, S.; Zalcberg, J. R.; Simes, J.; Karapetis, C. S.; Bardelli, A.; Tejpar, S. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA, 2010, 304(16), 1812-1820.
57. Di Nicolantonio, F.; Arena, S.; Tabernero, J.; Grosso, S.; Molinari, F.; Macarulla, T.; Russo, M.; Cancelliere, C.; Zecchin, D.; Mazzucchelli, L.; Sasazuki, T.; Shirasawa, S.; Geuna, M.; Frattini, M.; Baselga, J.; Gallicchio, M.; Biffo, S.; Bardelli, A. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest., 2010, 120(8), 2858-2866.
58. Rini, B. I.; Atkins, M. B. Resistance to targeted therapy in renalcell carcinoma. Lancet Oncol., 2009, 10(10), 992-1000.
59. Huang, D.; Ding, Y.; Zhou, M.; Rini, B. I.; Petillo, D.; Qian, C. N.; Kahnoski, R.; Futreal, P. A.; Furge, K. A.; Teh, B. T. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res., 2010, 70(3), 1063-1071.
60. Ciardiello, F.; Bianco, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, D.; De Vita, F.; De Placido, S.; Bianco, A. R.; Tortora, G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res., 2004, 10(2), 784-793.
61. Bianco, R.; Rosa, R.; Damiano, V.; Daniele, G.; Gelardi, T.; Garofalo, S.; Tarallo, V.; De Falco, S.; Melisi, D.; Benelli, R.; Albini, A.; Ryan, A.; Ciardiello, F.; Tortora, G. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin. Cancer Res., 2008, 14(16), 5069-5080.
62. Rosa, R.; Marciano, R.; Malapelle, U.; Formisano, L.; Nappi, L.; D'Amato, C.; D'Amato, V.; Damiano, V.; Marfe, G.; Del Vecchio, S.; Zannetti, A.; Greco, A.; De Stefano, A.; Carlomagno, C.; Veneziani, B. M.; Troncone, G.; De Placido, S.; Bianco, R. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin. Cancer Res., 2011, 19(1), 138-147.
63. Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, D. Anti-VEGF treatmentresistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin. Cancer Res., 2011, 17(17), 5822-5832.
64. Rexer, B. N.; Ham, A. J.; Rinehart, C.; Hill, S.; Granja-Ingram Nde, M.; Gonzalez-Angulo, A. M.; Mills, G. B.; Dave, B.; Chang, J. C.; Liebler, D. C.; Arteaga, C. L. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene, 2011, 30(40), 4163-4174.
65. Zhang, S.; Huang, W. C.; Li, P.; Guo, H.; Poh, S. B.; Brady, S. W.; Xiong, Y.; Tseng, L. M.; Li, S. H.; Ding, Z.; Sahin, A. A.; Esteva, F. J.; Hortobagyi, G. N.; Yu, D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med., 2011, 17(4), 461-469.
66. Donev, I. S.; Wang, W.; Yamada, T.; Li, Q.; Takeuchi, S.; Matsumoto, K.; Yamori, T.; Nishioka, Y.; Sone, S.; Yano, S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin. Cancer Res., 2011, 17(8), 2260-2269.
67. Tanizaki, J.; Okamoto, I.; Okabe, T.; Sakai, K.; Tanaka, K.; Hayashi, H.; Kaneda, H.; Takezawa, K.; Kuwata, K.; Yamaguchi, H.; Hatashita, E.; Nishio, K.; Nakagawa, K. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin. Cancer Res., 2012, 18(22), 6219-6226.
68. Arunasree, K. M.; Roy, K. R.; Anilkumar, K.; Aparna, A.; Reddy, G. V.; Reddanna, P. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk. Res., 2008, 32(6), 855-864.
69. Marfe, G.; Di Stefano, C.; Gambacurta, A.; Ottone, T.; Martini, V.; Abruzzese, E.; Mologni, L.; Sinibaldi-Salimei, P.; de Fabritis, P.; Gambacorti-Passerini, C.; Amadori, S.; Birge, R. B. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp. Hematol., 2011, 39(6), 653-665 e656.
70. Liu, L.; Wang, S.; Chen, R.; Wu, Y.; Zhang, B.; Huang, S.; Zhang, J.; Xiao, F.; Wang, M.; Liang, Y. Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem. Biophys. Res. Commun., 2012, 425(2), 368-373.
71. Monteleone, F.; Rosa, R.; Vitale, M.; D'Ambrosio, C.; Succoio, M.; Formisano, L.; Nappi, L.; Romano, M. F.; Scaloni, A.; Tortora, G.; Bianco, R.; Zambrano, N. Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics, 2013.
72. Bertotti, A.; Migliardi, G.; Galimi, F.; Sassi, F.; Torti, D.; Isella, C.; Cora, D.; Di Nicolantonio, F.; Buscarino, M.; Petti, C.; Ribero, D.; Russolillo, N.; Muratore, A.; Massucco, P.;Pisacane, A.; Molinaro, L.; Valtorta, E.; Sartore-Bianchi, A.; Risio, M.; Capussotti, L.; Gambacorta, M.; Siena, S.; Medico, E.; Sapino, A.; Marsoni, S.; Comoglio, P. M.; Bardelli, A.; Trusolino, L. A molecularly annotated platform of patient-derived xenografts (xenopatients) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov., 2012, 1(6), 508-523.